BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 10375185)

  • 1. Early results of radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation. The Prostate Cancer Study Group.
    Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y
    Int J Urol; 1999 May; 6(5):229-37; discussion 238-9. PubMed ID: 10375185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
    Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
    Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative endocrine therapy for clinical stage A2, B, and C prostate cancer: an interim report on short-term effects. Prostate Cancer Study Group.
    Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y
    Int J Urol; 1997 Mar; 4(2):144-51. PubMed ID: 9179687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group.
    McLeod DG; Johnson CF; Klein E; Peabody JO; Coffield S; Soloway M
    Urology; 1997 Mar; 49(3A Suppl):70-3. PubMed ID: 9123740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine therapy with or without radical prostatectomy for T1b-T3N0M0 prostate cancer.
    Homma Y; Akaza H; Okada K; Yokoyama M; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
    Int J Urol; 2004 Apr; 11(4):218-24. PubMed ID: 15028100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant hormonal therapy prior to radical prostatectomy: evaluation of pathological downstaging and biochemical relapse.
    Kiriyama I; Ogaki K; Ohba S; Nishimura T
    J Nippon Med Sch; 2002 Oct; 69(5):422-7. PubMed ID: 12382001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.
    Ravi P; Karnes RJ; Rangel LJ; Pagliaro LC
    J Urol; 2018 Nov; 200(5):1075-1081. PubMed ID: 29709664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
    Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
    J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer.
    Kurek R; Renneberg H; Lübben G; Kienle E; Tunn UW
    Eur Urol; 1999; 35 Suppl 1():27-31. PubMed ID: 10081700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer.
    Eulau SM; Tate DJ; Stamey TA; Bagshaw MA; Hancock SL
    Int J Radiat Oncol Biol Phys; 1998 Jul; 41(4):735-40. PubMed ID: 9652832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction androgen deprivation plus prostatectomy for stage T3 disease: failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial.
    Gomella LG; Liberman SN; Mulholland SG; Petersen RO; Hyslop T; Corn BW
    Urology; 1996 Jun; 47(6):870-7. PubMed ID: 8677579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer.
    Cher ML; Shinohara K; Breslin S; Vapnek J; Carroll PR
    Br J Urol; 1995 Jun; 75(6):771-7. PubMed ID: 7542137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stage T3 prostate cancer: a nonrandomized comparison between definitive irradiation and induction hormonal manipulation plus prostatectomy.
    Corn BW; Valicenti RK; Mulholland SG; Hyslop T; Gomella L
    Urology; 1998 May; 51(5):782-7. PubMed ID: 9610592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results.
    Soloway MS; Pareek K; Sharifi R; Wajsman Z; McLeod D; Wood DP; Puras-Baez A;
    J Urol; 2002 Jan; 167(1):112-6. PubMed ID: 11743286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group.
    Soloway MS; Sharifi R; Wajsman Z; McLeod D; Wood DP; Puras-Baez A
    J Urol; 1995 Aug; 154(2 Pt 1):424-8. PubMed ID: 7541859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate specific antigen doubling time after radical prostatectomy: effect of neoadjuvant androgen deprivation therapy.
    Rabbani F; Perrotti M; Bastar A; Fair WR
    J Urol; 1999 Mar; 161(3):847-52. PubMed ID: 10022699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative androgen deprivation therapy: artificial lowering of serum prostate specific antigen without downstaging the tumor.
    Oesterling JE; Andrews PE; Suman VJ; Zincke H; Myers RP
    J Urol; 1993 Apr; 149(4):779-82. PubMed ID: 7681117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive disease.
    Spahn M; Briganti A; Capitanio U; Kneitz B; Gontero P; Karnes JR; Schubert M; Montorsi F; Scholz CJ; Bader P; van Poppel H; Joniau S;
    J Urol; 2012 Jul; 188(1):84-90. PubMed ID: 22578727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen deprivation prior to radical prostatectomy for T2b and T3 prostate cancer.
    Soloway MS; Hachiya T; Civantos F; Murphy WM; Gomez CC; Ruiz HE
    Urology; 1994 Feb; 43(2 Suppl):52-6. PubMed ID: 7509535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.